2018 Operating Grant Recipients

Donations to The Leukemia & Lymphoma Society of Canada contribute to blood cancer research funding. There are many scientists in hospitals and cancer centres across the country who are looking for financial support in order to start or continue their projects in blood cancer research. 

The Leukemia & Lymphoma Society of Canada has a long-standing history of funding cancer research that began in 1955 when five Toronto women concerned about the lack of leukemia research started fundraising. Today, we are the largest voluntary health agency in Canada that is dedicated not only to leukemia but to all types of blood cancers. 

In 2018, we invested more than $2.8 million in our Operating Grants, which will support the work of 14 new research projects in addition to those selected in 2017.

Donate Today      

Complete list of 2018 Researchers


2018 Operating Grant Award Winners

Dr. Frédéric Barabé

University of Laval
Québec City, Québec Co-Applicant: Dr. Philippe Tessier Blood cancer type
acute myeloid leukemia (AML)   The study Biology of S100A8 and S100A9 proteins in human AML Our team has recently studied the role of S100A8 and S100A9 proteins in acute myeloid leukemias. We found that S100A8 maintains the undifferentiated state of leukemic cells while S100A9 can induce...

Dr. Jason Berman

IWK Health Centre
Halifax, Nova Scotia Blood cancer type
Leukemia The study DNAJC21 a novel leukemia predisposition gene in Shwachman-Diamond Syndrome Mutations in a gene called DNAJC21 were recently found to cause Shwachman-Diamond syndrome (SDS). Patients affected by SDS have low numbers of white blood cells, characteristic physical findings, and an increased risk of developing leukemia. I...

Dr. Mick Bhatia

McMaster University
Hamilton, Ontario Blood cancer type
acute myeloid leukemia (AML) The study Defining targets of MDS to AML progression Leukemia impacts thousands of Canadians. Developing effective treatments is limited by incomplete understanding of how normal blood cells become leukemic in the first place. Using our recently created model system where normal blood cells can be progressiv...

Dr. Joseph Brandwein

University of Alberta
Edmonton, Alberta Co-Applicant: Dr. Luc Berthiaume                                            
University of Alberta Co-Applicant: Dr. David Sanford
BC Canc...

Dr. Rena Buckstein

Sunnybrook Health Sciences Centre
Toronto, Ontario
Recipient of 2018 UFCW Canada Award for Leukemia Research Co-Applicant: Dr. Michael Rauh​
Queens University, Kingston, ON Blood cancer type
lymphoma   The study Clonal Hemopoiesis is a Risk Factor for Chemotherapy-Related Complications  This study will screen 188 lymphoma patients, over the age of 60, prior to...

Dr. Sonia Cellot

CHU Ste-Justine, University of Montréal
Montréal, Québec​ Co-Applicant: Dr. Mélanie Bilodeau​
CHU Ste-Justine, University of Montréal   Blood cancer type
Pediatric acute myeloid leukemia (AML)   The study Uncovering the role of NEO1 in NUP98 acute megakaryoblastic leukemia  AML represents 20% of pediatric leukemia, but accounts for most of disease-rela...

Dr. Hong Chang

University Health Network
Toronto, Ontario Blood cancer type
Multiple myeloma The study Role of Epigenetic Modulation in Myeloma Drug Resistance Multiple myeloma (MM) is a B-cell tumor with survival ranging from several months to a few years. It remains incurable due to the development of a drug-resistant phenotype after prolonged therapy. Current studies focus on the targeted therapy with m...

Dr. Rodney DeKoter

University of Western Ontario
London, Ontario

Blood cancer type
B-cell acute lymphoblastic leukemia (B-ALL) The study Characterization of driver mutations in a mouse model of B-cell leukemia We have developed a new mouse model of pediatric precursor B-cell acute lymphoblastic leukemia (B-ALL). Our goal is to identify mutations responsible for driving cancer development in these m...

Dr. Mani Larijani

Memorial University of Newfoundland
St. John’s, Newfoundland Blood cancer type
lymphoma and leukemia   The study Developing and testing AID inhibitors for leukemia/lymphoma treatment We are studying a molecule called AID which mutates the DNA of lymphocytes thus transforming them into leukemia or lymphomas. Many studies have shown conclusively that AID expression in lymphomas corre...

Dr. David LeBrun

Queen’s University
Kingston, Ontario Co-Applicant: Dr. Lincoln Stein
Ontario Institute for Cancer Research
Toronto, Ontario   Blood cancer type
B-cell lymphoma   The study Identifying non-coding driver mutations in diffuse large B-cell lymphoma DNA sequencing studies of Diffuse large B-cell (DLBC) lymphoma patients have revealed that 99% of their cancer-ass...

Dr. Alexandre Orthwein

Jewish General Hospital/Lady Davis Institute for Medical Research
Montréal, Québec​ Co-Applicant: Dr. Nathalie Johnson                          
Collaborator: Dr. Francois Mercier
JGH/LDI         &nb...

Dr. Claude Perreault

University of Montréal
Montréal, Québec​ Blood cancer type
acute myeloid leukemia (AML)   The study The molecular landscape of leukemia-specific antigens The goal of our project is to develop therapeutic vaccines against acute myeloid leukemia (AML). We therefore need to discover molecules that are present only on leukemic cells and that can be recognized by the immune system. T...

Dr. Leonardo Salmena

University of Toronto
Toronto, Ontario Co-Applicant: Dr. Zhaolei Zhang
University of Toronto   Blood cancer type
acute myeloid leukemia (AML)   The study Identification of microRNAs essential for AML chemoresistance  Chemoresistance is one of the primary targets of AML research because there is tremendous potential to increase survival if overcome. Nevertheless...

Dr. Kirk Schultz

University of British Columbia
Vancouver, British Columbia Co-Applicant: Dr. Sara Mostafavi​
University of British Columbia Blood cancer type
pediatric leukemia   The study Validation of Pediatric Chronic Graft-Versus-Host Disease Biomarkers     When children have leukemia, we treat them using transplantation of blood or bone marrow donated from anothe...